LN – Moderna: FDA delays decision on its adolescent vaccine



CAMBRIDGE, Massachusetts, U.S. (AP) – U.S. regulators are delaying their decision on applying Moderna’s COVID-19 vaccine to children ages 12 to 17 as they study an unusual risk of heart inflammation that can provoke, the drugmaker reported Sunday.

The US Food and Drug Administration (FDA) told the company on Friday that its review could take until January, Moderna said.

The company also indicated that it will delay the submission of an application for authorization for emergency use of a lower dose of the vaccine for children 6 to 11 years old.

Inflammation of the heart is an extremely rare risk in both the Moderna and Pfizer vaccines, and is seen most often in young men and boys. It is difficult to detect the problem in clinical trials. And public health authorities have repeatedly stressed that COVID-19 itself can cause inflammation at a higher incidence than rare cases caused by the vaccine.

In the United States, Moderna’s vaccine is licensed for use in those 18 years of age and older.

Moderna pointed out that more than 1.5 million adolescents worldwide have received the vaccine and that the number of reports of heart inflammation “does not suggest an increased risk” for those under 18 years of age.

In the United States, children ages 12 to 17 can receive the vaccine produced by Pfizer and its partner BioNTech.

The FDA took action last week to allow the use of Pfizer’s vaccine in children ages 5 to 11. The Centers for Disease Control and Prevention (CDC) will debate the issue this week.

Moderna has also been testing two injections, one month apart, for children ages 6 to 11, with half the dose for adults.



Publicado en el diario La Nación

(Visitado 4 veces, 1 visitas hoy)